Sensei Biotherapeutics (NASDAQ:FTH) Trading 7.4% Higher – What’s Next?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price was up 7.4% on Thursday . The stock traded as high as $38.41 and last traded at $38.7930. 40,523 shares traded hands during trading, a decline of 81% from the average session volume of 214,469 shares. The stock had previously closed at $36.12.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. TD Cowen assumed coverage on Sensei Biotherapeutics in a research note on Wednesday. They issued a “buy” rating on the stock. Citigroup started coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 target price for the company. Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a research report on Thursday, May 28th. Citizens Jmp began coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective for the company. Finally, Needham & Company LLC assumed coverage on Sensei Biotherapeutics in a report on Friday, August 21st. They set a “buy” rating and a $56.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Stock Performance

The business has a fifty day moving average price of $30.73. The company has a market capitalization of $973.01 million, a PE ratio of -0.26 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, sell-side analysts predict that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Insider Activity at Sensei Biotherapeutics

In related news, CEO Anand Kiran Parikh acquired 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Brian C. Stephenson acquired 9,391 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was purchased at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the transaction, the chief financial officer directly owned 26,804 shares in the company, valued at approximately $700,388.52. The trade was a 53.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 49,494 shares of company stock valued at $1,188,822 in the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several large investors have recently made changes to their positions in FTH. Renaissance Technologies LLC increased its position in Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after purchasing an additional 1,100 shares during the period. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics during the 1st quarter valued at about $4,188,000. Bank of America Corp DE boosted its stake in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $22,758,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics during the 2nd quarter worth approximately $3,610,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.